BioAge Labs, Inc.: UBS initiates coverage with neutral rating and $8 target price
BIOA•UBS initiated coverage of BioAge Labs with a neutral rating and an $8 target price.
BIOA•BIOA•BIOA•UBS initiated coverage of BioAge Labs with a neutral rating and an $8 target price.
